关于佐剂在开发高效 COVID-19 疫苗中的作用的观点。
A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines.
机构信息
Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou 310015, China.
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China.
出版信息
Viruses. 2022 Feb 14;14(2):387. doi: 10.3390/v14020387.
Abstract
Several countries have made unremitting efforts to develop an optimal vaccine in the fight against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the increasing occurrence of SARS-CoV-2 variants, current vaccines show decreased neutralizing activities, especially towards the Omicron variant. In this context, adding appropriate adjuvants to COVID-19 vaccines can substantially reduce the number of required doses and improve efficacy or cross-neutralizing protection. We mainly focus on research progress and achievements associated with adjuvanted COVID-19 subunit and inactivated vaccines. We further compare the advantages and disadvantages of different adjuvant formulations in order to provide a scientific reference for designing an effective strategy for future vaccine development.
摘要
为应对由严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19），一些国家一直在不懈努力研发最佳疫苗。随着 SARS-CoV-2 变异株的不断出现，目前的疫苗显示出中和活性降低，尤其是针对奥密克戎变异株。在此背景下，在 COVID-19 疫苗中添加适当的佐剂可以显著减少所需剂量，并提高疗效或交叉中和保护作用。我们主要关注与佐剂 COVID-19 亚单位和灭活疫苗相关的研究进展和成果。我们进一步比较了不同佐剂配方的优缺点，以期为未来疫苗开发的有效策略设计提供科学参考。
相似文献
1
A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines.关于佐剂在开发高效 COVID-19 疫苗中的作用的观点。
Viruses. 2022 Feb 14;14(2):387. doi: 10.3390/v14020387.
2
3
A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.一种基于人体细胞的 SARS-CoV-2 疫苗可引发强烈的中和抗体反应，并可保护小鼠免受 SARS-CoV-2 攻击。
Emerg Microbes Infect. 2021 Dec;10(1):1555-1573. doi: 10.1080/22221751.2021.1957400.
4
Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.严重急性呼吸综合征相关冠状病毒异源感染期间，灭活严重急性呼吸综合征冠状病毒2疫苗的佐剂依赖性影响。
Nat Commun. 2024 May 3;15(1):3738. doi: 10.1038/s41467-024-47450-x.
5
Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.一种灭活的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒疫苗诱导的中和抗体的分子去卷积分析
Protein Cell. 2021 Oct;12(10):818-823. doi: 10.1007/s13238-021-00840-z. Epub 2021 Apr 28.
6
Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice.比较铝佐剂和 MF59 样佐剂灭活 SARS-CoV-2 疫苗在老年小鼠中对 SARS-CoV-2 变异株的免疫原性。
Viral Immunol. 2023 Oct;36(8):526-533. doi: 10.1089/vim.2023.0041. Epub 2023 Aug 25.
7
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
8
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.《COVID-19 疫苗研发的进展与挑战综述》。
Front Immunol. 2020 Oct 14;11:585354. doi: 10.3389/fimmu.2020.585354. eCollection 2020.
9
Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.序贯免疫 SARS-CoV-2 RBD 疫苗可诱导小鼠产生针对变异株的强效和广谱中和抗体。
Virol J. 2022 Jan 4;19(1):2. doi: 10.1186/s12985-021-01737-3.
10
A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.一种靶向淋巴结的两亲体疫苗诱导针对 SARS-CoV-2 的强烈细胞和体液免疫。
Sci Adv. 2021 Feb 5;7(6). doi: 10.1126/sciadv.abe5819. Print 2021 Feb.
引用本文的文献
1
Engineered Salmonella Enteritidis vector targeting innate immune molecules provides protection against Salmonella Enteritidis and Salmonella Typhimurium.靶向天然免疫分子的工程化肠炎沙门氏菌载体可提供针对肠炎沙门氏菌和鼠伤寒沙门氏菌的保护。
Poult Sci. 2025 Aug 24;104(11):105724. doi: 10.1016/j.psj.2025.105724.
2
A Dual-Adjuvanted Parenteral-Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS-CoV-2 in Mice.一种双佐剂肠胃外-鼻内亚单位纳米疫苗在小鼠中产生针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的强大全身和黏膜免疫。
Adv Sci (Weinh). 2024 Dec;11(45):e2402792. doi: 10.1002/advs.202402792. Epub 2024 Oct 1.
3
Hybrid response to SARS-CoV-2 and C after an OMV-adjuvanted immunization in mice and their offspring.在小鼠及其后代中，用 OMV 佐剂免疫后对 SARS-CoV-2 和 C 的混合反应。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2346963. doi: 10.1080/21645515.2024.2346963. Epub 2024 May 15.
4
Vaccine adjuvants: current status, research and development, licensing, and future opportunities.疫苗佐剂：现状、研究与开发、许可和未来机遇。
J Mater Chem B. 2024 May 1;12(17):4118-4137. doi: 10.1039/d3tb02861e.
5
Case report: Neglected subacute thyroiditis: a case following COVID-19 vaccination.病例报告：被忽视的亚急性甲状腺炎：1例新冠病毒疫苗接种后的病例
Front Med (Lausanne). 2024 Mar 8;11:1349615. doi: 10.3389/fmed.2024.1349615. eCollection 2024.
6
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.RAZI 重组刺突蛋白疫苗（RCP）作为 BBIBP-CorV 初免后的加强针的免疫原性和安全性：一项平行、两组、随机、双盲试验。
BMC Med. 2024 Feb 20;22(1):78. doi: 10.1186/s12916-024-03295-1.
7
Adjuvants for COVID-19 Vaccines.新冠疫苗佐剂
Vaccines (Basel). 2023 Apr 26;11(5):902. doi: 10.3390/vaccines11050902.
8
An assessment of the strategy and status of COVID-19 vaccination in India.印度 COVID-19 疫苗接种策略和现状评估。
Immunol Res. 2023 Aug;71(4):565-577. doi: 10.1007/s12026-023-09373-5. Epub 2023 Apr 11.
9
Immune-mediated liver injury following COVID-19 vaccination.新型冠状病毒肺炎疫苗接种后的免疫介导性肝损伤
World J Virol. 2023 Mar 25;12(2):100-108. doi: 10.5501/wjv.v12.i2.100.
10
Cellular Sensors and Viral Countermeasures: A Molecular Arms Race between Host and SARS-CoV-2.细胞传感器与病毒对策：宿主与 SARS-CoV-2 间的分子军备竞赛。
Viruses. 2023 Jan 26;15(2):352. doi: 10.3390/v15020352.
本文引用的文献
1
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.新型冠状病毒病佐剂亚单位蛋白疫苗（SCB-2019）的有效性：一项 2 期和 3 期、多中心、双盲、随机、安慰剂对照试验。
Lancet. 2022 Jan 29;399(10323):461-472. doi: 10.1016/S0140-6736(22)00055-1. Epub 2022 Jan 20.
2
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.一种新型 STING 激动剂佐剂的泛沙贝科病毒疫苗在小鼠、兔和非人灵长类动物中引发了强烈和持久的中和抗体和 T 细胞应答。
Cell Res. 2022 Mar;32(3):269-287. doi: 10.1038/s41422-022-00612-2. Epub 2022 Jan 19.
3
RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern.含 TLR1/2 激动剂的 RBD 结合疫苗对 SARS-CoV-2 及其关注变体具有高度免疫原性。
Chem Commun (Camb). 2022 Feb 10;58(13):2120-2123. doi: 10.1039/d1cc06520c.
4
A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge.两佐剂多抗原候选疫苗诱导针对 SARS-CoV-2 挑战的优越保护免疫应答。
Cell Rep. 2021 Dec 14;37(11):110112. doi: 10.1016/j.celrep.2021.110112. Epub 2021 Nov 24.
5
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.使用双 Toll 样受体配体脂质体佐剂开发 COVID-19 疫苗。
NPJ Vaccines. 2021 Nov 18;6(1):137. doi: 10.1038/s41541-021-00399-0.
6
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.一种灭活的严重急性呼吸综合征冠状病毒 2 型疫苗（BBV152）的有效性、安全性和批间免疫原性：一项随机、双盲、对照、3 期临床试验的中期结果。
Lancet. 2021 Dec 11;398(10317):2173-2184. doi: 10.1016/S0140-6736(21)02000-6. Epub 2021 Nov 11.
7
Delivery of STING agonists for adjuvanting subunit vaccines.STING 激动剂在佐剂亚单位疫苗中的递送。
Adv Drug Deliv Rev. 2021 Dec;179:114020. doi: 10.1016/j.addr.2021.114020. Epub 2021 Oct 29.
8
Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.用于 SARS-CoV-2 的 BIV1-CovIran 灭活候选疫苗的安全性和效力：一项临床前研究。
Rev Med Virol. 2022 May;32(3):e2305. doi: 10.1002/rmv.2305. Epub 2021 Oct 26.
9
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant.通过与聚合糖佐剂缀合，产生针对 SARS-CoV-2 抗原的有效细胞和体液免疫。
Biomaterials. 2021 Nov;278:121159. doi: 10.1016/j.biomaterials.2021.121159. Epub 2021 Sep 30.
10
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.一种用于诱导重组 SARS-CoV-2 蛋白疫苗产生有效抗病毒免疫应答的联合佐剂。
Front Immunol. 2021 Sep 16;12:729189. doi: 10.3389/fimmu.2021.729189. eCollection 2021.
Zotero 插件